Vinay Prasad to Rejoin FDA After Abrupt Departure

Less than weeks after stepping down, Prasad will return to lead CBER “at the FDA’s request,” according to an HHS spokesperson, marking the latest twist in an unusual run leading the FDA office overseeing vaccines and gene therapy.